Pediatric mycoplasma infections can be treated with azithromycin provided that there is no allergy to azithromycin.
Azithromycin belongs to the class of macrolide antibiotics, which can inhibit protein synthesis and has high antibacterial activity against Mycoplasma.
The pharmacokinetics of the drug is unique in that its concentration at sites of inflammation is much higher than that at non-inflammatory sites, and the concentration of drug inhibition is low. The damage to the gastrointestinal tract and liver is lower than that of other macrolides, and it is commonly used in the treatment of pediatric mycoplasma infections.
However, the drug may still cause some adverse reactions, such as pain at the injection site, rash, nausea, diarrhea, etc. It is contraindicated for those who are allergic to the drug. According to the specific condition of the pediatric patient, the dosage of the drug needs to be adjusted by a professional doctor.